TAKEDA PHARMACEUTICAL CO LTD
TAKThe Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect".
Drugs in Pipeline
200
Phase 3 Programs
134
Upcoming Catalysts
9
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
13 upcoming, 1 past
TAK-360 Phase 2 Est. Readout
Primary completion for TAK-360 trial (NCT06952699) in Narcolepsy Type 2
AI-designed pill achieved total skin clearance in >35% of patients at 16 weeks, >2.5x control arm with Sotyktu
SourceTetravalent Dengue Vaccine (TDV) Phase 3 Est. Readout
Primary completion for Tetravalent Dengue Vaccine (TDV) trial (NCT07047521) in Dengue Fever
zasocitinib outperformed Sotyktu in Phase III PsA trial
Source11 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
TAK-559
Diabetes Mellitus
HYQVIA
Primary Immunodeficiency Diseases (PID)
Bismuth-Containing Quadruple Therapy
Duodenal Ulcer
Mezagitamab
Immune Thrombocytopenic Purpura (ITP)
Azilsartan Medoxomil and amlodipine
Hypertension
Active Comparator
Psoriatic Arthritis
Soticlestat
Dravet Syndrome (DS)
Lansoprazole
Esophagitis, Reflux
Alogliptin and voglibose
Type 2 Diabetes Mellitus
Dexlansoprazole MR QD
Gastroesophageal Reflux
Vedolizumab IV
Moderately to Severely Active Ulcerative Colitis
Deucravacitinib
Plaque Psoriasis
Epoetin
Chronic Kidney Disease
von Willebrand factor (Recombinant)
Von Willebrand Disease
IGSC 20% infusion
Primary Immunodeficiency Disease
Glipizide
Diabetes Mellitus
Azilsartan medoxomil and olmesartan
Hypertension
Vortioxetine
Major Depressive Disorder
Lu AA21004
Major Depressive Disorder
TAK-536TCH tablet
Essential Hypertension
YF-17D
Dengue
Ixazomib Citrate
Multiple Myeloma
Rosiglitazone
Diabetes Mellitus
TAK-881
Primary Immunodeficiency Diseases (PID)
Lapaquistat acetate and simvastatin
Hypercholesterolemia
Upadacitinib
Crohn's Disease
MOVIPREP
Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.
Velaglucerase Alfa
Gaucher Disease
Lapaquistat acetate and rosuvastatin
Hypercholesterolemia
TAK-279
Plaque Psoriasis
NE-58095 IR
Involutional Osteoporosis
9vHPV Vaccine
Dengue Fever
Relugolix
Uterine Fibroids
Teduglutide
Short Bowel Syndrome
Vonoprazan
Gastroesophageal Reflux
TVP-1012
Parkinson's Disease
Actovegin
Peripheral Arterial Diseases
Zopiclone
Balance
TachoSil®
Hemorrhage
TAK-536
Hypertension
REPLAGAL
Fabry Disease
Elritercept
Myelodysplastic Syndromes
Dexlansoprazole
Gastroesophageal Reflux Disease
Ramipril
Hypertension
Valsartan
Hypertension
Febuxostat
Gout
TAK-672
Acquired Hemophilia A
Apremilast
Plaque Psoriasis
TAK-330
Coagulation Disorder
Voglibose
Type 2 Diabetes Mellitus
TAK-771
Primary Immunodeficiency Diseases (PID)
Surgicel® Original
Bleeding
TAP-144-SR(6M)
Prostate Cancer
Vedolizumab SC
Ulcerative Colitis
Fasiglifam
Diabetes Mellitus, Type 2
Alogliptin Benzoate
Diabetes Mellitus, Type 2
Febuxostat IR
Gout
TAK-360
Idiopathic Hypersomnia
TVP-1012 1mg
Parkinson's Disease
Lubiprostone
Constipation
Gefarnate
Stomach Ulcer
TAK-755
Thrombotic Thrombocytopenic Purpura (TTP)
Metformin HCl
Diabetes Mellitus
TAK-667
Hereditary Angioedema
Leuprorelin SR
Prostatic Neoplasms, Locally Advanced
VONVENDI
Von Willebrand Disease (VWD)
Intranasal Fentanyl Spray (INFS)
Break Through Pain
TVP-1012 0.5mg
Parkinson's Disease
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
Dengue Fever
Metformin hydrochloride
Type 2 Diabetes Mellitus
Azilsartan
Hypertension
Alogliptin and pioglitazone
Type 2 Diabetes Mellitus
Lansoprazole microgranules suspension
Gastroesophageal Reflux Disease
Concomitant Antibiotic Therapy
Pouchitis
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
Hypertension
Alogliptin and metformin
Type 2 Diabetes Mellitus
TAK-743 300 mg
Hereditary Angioedema
Parathyroid Hormone (PTH)
Osteoporosis
Cyclobenzaprine HCl
Neck Pain
TAK-625
Alagille Syndrome (ALGS)
Fazirsiran Injection
Alpha1-Antitrypsin Deficiency
TAK-875
Diabetes Mellitus
Lapaquistat Acetate
Dyslipidemia
TAK-003
Dengue Fever
TAK-816
Healthy Volunteers
Brigatinib
ALK-positive Advanced NSCLC
Lapaquistat acetate and atorvastatin
Hypercholesterolemia
Cyproterone acetate
Adenocarcinoma, Prostate
Escitalopram
Treatment Outcome
Maribavir
Cytomegalovirus (CMV)
Tetravalent Dengue Vaccine (TDV)
Dengue Fever
TAK-816+ DPT-TAKEDA
Immunization
Lapaquistat acetate and lipid-lowering therapy
Type 2 Diabetes
Glyburide
Diabetes Mellitus
Lapaquistat acetate and additional lipid-lowering therapy
Hypercholesterolemia
Alectinib
ALK+ Advanced NSCLC
HAV Vaccine
Healthy Volunteers
Ramelteon
Sleep Initiation and Maintenance Disorders
TDV
Dengue Fever
Dexlansoprazole MR
Gastroesophageal Reflux Disease
Ixazomib
Multiple Myeloma
SYR-472
Diabetes Mellitus
TAK-583
Neuralgia, Postherpetic
Darvadstrocel
Crohn's Disease
Omega-3-acid ethyl esters 90 (TAK-085)
Hypertriglyceridemia
TAK-536CCB
Grade I or II Essential Hypertension
Lansoprazole and naproxen and aspirin
Osteoarthritis
Vedolizumab
Colitis, Ulcerative
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Colorectal Cancer
Rapid-acting insulin secretagogue
Diabetes Mellitus
TAK-861
Narcolepsy Type 1
Pioglitazone and Metformin
Diabetes Mellitus
Idursulfase-IT
Hunter Syndrome
Lanadelumab
Angioedema
Candesartan
Heart Failure
Venticute
Pneumonia
Alogliptin
Diabetes Mellitus, Type 2
Azilsartan medoxomil - chlorthalidone
Essential Hypertension
Vortioxetine tablets
Major Depressive Disorder
Azilsartan medoxomil
Essential Hypertension
Zasocitinib
Psoriatic Arthritis
Leuprorelin
Prostatic Neoplasms
Resatorvid
Sepsis
Vedolizumab 300 mg IV
Colitis, Ulcerative
Vedolizumab SC 108 mg
Crohn's Disease
TAK-019
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Alogliptin and glyburide
Diabetes Mellitus
TAK-438
Gastric Ulcers
SYR-322-MET
Clinical Pharmacology
TAK-438 10 mg
Non-erosive Gastroesophageal Reflux Disease
Vonicog Alfa
Von Willebrand Disease (VWD)
Azilsartan medoxomil and chlorthalidone
Essential Hypertension
Chlorthalidone
Hypertension
Adynovate
Hemophilia A
TAK-411
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
Dengue Fever
Leuprorelin acetate
Endometriosis
Zasocitinib (Dose A)
Hidradenitis Suppurativa
Norwalk VLP vaccine
Acute Gastroenteritis
NoV Vaccine
Healthy Volunteers
TAK-981
Advanced or Metastatic Solid Tumors
TAK-954
Postoperative Gastrointestinal Dysfunction
TAK-079
Primary Immune Thrombocytopenia
TAK-063 20 mg
Schizophrenia
MCC-135
Congestive Heart Failure
Brentuximab Vedotin
Lymphoma
Panitumumab + TAS-102
Colorectal Cancer
Pevonedistat
Acute Myeloid Leukemia (AML)
TAK-071
Parkinson Disease
Leuprorelin (GF)
Uterine Fibroids
Olmesartan
Hypertension
Candesartan cilexetil
Essential Hypertension
Lapaquistat acetate and fenofibrate
Hyperlipidemias
Peginesatide
Anemia
Hepatitis A Vaccine
Healthy Volunteers
NoV GI.1/GII.4 Bivalent VLP Vaccine
Norovirus
TAK-007
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Ponatinib
Myeloid Leukemia, Chronic, Chronic Phase
TAK-853
Ovarian Cancer
TAK-850 0.5 mL injection
Influenza Infection
TIMP-GLIA
Celiac Disease
TAK-662
Congenital Protein C Deficiency
TAK-850
Influenza Infection
GDX012
Leukemia
TAK-188
Advanced or Metastatic Solid Tumors
Levothyroxine sodium new formulation
Hypothyroidism
TD-8954
Enteral Feeding Intolerance
Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Dengue Fever
TAK-341
Multiple System Atrophy
Norovirus Bivalent VLP Vaccine
Norovirus Prevention
TAK-442
Acute Coronary Syndrome
vortioxetine (Lu AA21004)
Depressive Disorder, Major
NDI-034858
Psoriatic Arthritis
TAK-062
Celiac Disease
Pioglitazone and insulin
Diabetes Mellitus
Ramelteon and doxepin
Sleep Initiation and Maintenance Disorders
Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Norovirus
Subcutaneous injection of TAK-850
Influenza Infection
TAK-861 2 mg
Narcolepsy Type 2
TAK-128
Diabetic Neuropathies
TAK-385
Uterine Fibroids
TAK-101
Celiac Disease
Dazostinag
Solid Neoplasms
TAK-919
Coronavirus Disease (COVID-19)
TAK-783 and methotrexate
Arthritis, Rheumatoid
Norovirus Bivalent Vaccine
Prevention From Norovirus Infection
Ilaprazole
Esophagitis
TDV Liquid Formulation 1
Dengue Fever
Pioglitazone and atorvastatin
Cardiovascular Diseases
TAK-272
Type 2 Diabetes Mellitus and Microalbuminuria
GI.1/GII.4 (15/15)
Norovirus
TAK-951
Postoperative Nausea and Vomiting (PONV)
NDI-034858 study drug
Moderate to Severe Plaque Psoriasis
Namilumab
Rheumatoid Arthritis
TAK-788
Carcinoma, Non-Small-Cell Lung
Pioglitazone and ramipril
Inflammation
TAK-935
Developmental and/or Epileptic Encephalopathies
TAK-715 and methotrexate
Arthritis, Rheumatoid
Niraparib
Ovarian Cancer
Pioglitazone and azilsartan
Diabetes Mellitus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TAK-559 | Phase 3 | Diabetes Mellitus | - | - |
HYQVIA | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Bismuth-Containing Quadruple Therapy | Phase 3 | Duodenal Ulcer | - | - |
Mezagitamab | Phase 3 | Immune Thrombocytopenic Purpura (ITP) | - | - |
Azilsartan Medoxomil and amlodipine | Phase 3 | Hypertension | - | - |
Active Comparator | Phase 3 | Psoriatic Arthritis | - | - |
Soticlestat | Phase 3 | Dravet Syndrome (DS) | - | - |
Lansoprazole | Phase 3 | Esophagitis, Reflux | - | - |
Alogliptin and voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Dexlansoprazole MR QD | Phase 3 | Gastroesophageal Reflux | - | - |
Vedolizumab IV | Phase 3 | Moderately to Severely Active Ulcerative Colitis | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
Epoetin | Phase 3 | Chronic Kidney Disease | - | - |
von Willebrand factor (Recombinant) | Phase 3 | Von Willebrand Disease | - | - |
IGSC 20% infusion | Phase 3 | Primary Immunodeficiency Disease | - | - |
Glipizide | Phase 3 | Diabetes Mellitus | - | - |
Azilsartan medoxomil and olmesartan | Phase 3 | Hypertension | - | - |
Vortioxetine | Phase 3 | Major Depressive Disorder | - | - |
Lu AA21004 | Phase 3 | Major Depressive Disorder | - | - |
TAK-536TCH tablet | Phase 3 | Essential Hypertension | - | - |
YF-17D | Phase 3 | Dengue | - | - |
Ixazomib Citrate | Phase 3 | Multiple Myeloma | - | - |
Rosiglitazone | Phase 3 | Diabetes Mellitus | - | - |
TAK-881 | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Lapaquistat acetate and simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Upadacitinib | Phase 3 | Crohn's Disease | - | - |
MOVIPREP | Phase 3 | Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel. | - | - |
Velaglucerase Alfa | Phase 3 | Gaucher Disease | - | - |
Lapaquistat acetate and rosuvastatin | Phase 3 | Hypercholesterolemia | - | - |
TAK-279 | Phase 3 | Plaque Psoriasis | - | - |
NE-58095 IR | Phase 3 | Involutional Osteoporosis | - | - |
9vHPV Vaccine | Phase 3 | Dengue Fever | - | - |
Relugolix | Phase 3 | Uterine Fibroids | - | - |
Teduglutide | Phase 3 | Short Bowel Syndrome | - | - |
Vonoprazan | Phase 3 | Gastroesophageal Reflux | - | - |
TVP-1012 | Phase 3 | Parkinson's Disease | - | - |
Actovegin | Phase 3 | Peripheral Arterial Diseases | - | - |
Zopiclone | Phase 3 | Balance | - | - |
TachoSil® | Phase 3 | Hemorrhage | - | - |
TAK-536 | Phase 3 | Hypertension | - | - |
REPLAGAL | Phase 3 | Fabry Disease | - | - |
Elritercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Dexlansoprazole | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Ramipril | Phase 3 | Hypertension | - | - |
Valsartan | Phase 3 | Hypertension | - | - |
Febuxostat | Phase 3 | Gout | - | - |
TAK-672 | Phase 3 | Acquired Hemophilia A | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
TAK-330 | Phase 3 | Coagulation Disorder | - | - |
Voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
TAK-771 | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Surgicel® Original | Phase 3 | Bleeding | - | - |
TAP-144-SR(6M) | Phase 3 | Prostate Cancer | - | - |
Vedolizumab SC | Phase 3 | Ulcerative Colitis | - | - |
Fasiglifam | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Alogliptin Benzoate | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Febuxostat IR | Phase 3 | Gout | - | - |
TAK-360 | Phase 3 | Idiopathic Hypersomnia | - | - |
TVP-1012 1mg | Phase 3 | Parkinson's Disease | - | - |
Lubiprostone | Phase 3 | Constipation | - | - |
Gefarnate | Phase 3 | Stomach Ulcer | - | - |
TAK-755 | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP) | - | - |
Metformin HCl | Phase 3 | Diabetes Mellitus | - | - |
TAK-667 | Phase 3 | Hereditary Angioedema | - | - |
Leuprorelin SR | Phase 3 | Prostatic Neoplasms, Locally Advanced | - | - |
VONVENDI | Phase 3 | Von Willebrand Disease (VWD) | - | - |
Intranasal Fentanyl Spray (INFS) | Phase 3 | Break Through Pain | - | - |
TVP-1012 0.5mg | Phase 3 | Parkinson's Disease | - | - |
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) | Phase 3 | Dengue Fever | - | - |
Metformin hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Azilsartan | Phase 3 | Hypertension | - | - |
Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Lansoprazole microgranules suspension | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Concomitant Antibiotic Therapy | Phase 3 | Pouchitis | - | - |
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. | Phase 3 | Hypertension | - | - |
Alogliptin and metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
TAK-743 300 mg | Phase 3 | Hereditary Angioedema | - | - |
Parathyroid Hormone (PTH) | Phase 3 | Osteoporosis | - | - |
Cyclobenzaprine HCl | Phase 3 | Neck Pain | - | - |
TAK-625 | Phase 3 | Alagille Syndrome (ALGS) | - | - |
Fazirsiran Injection | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
TAK-875 | Phase 3 | Diabetes Mellitus | - | - |
Lapaquistat Acetate | Phase 3 | Dyslipidemia | - | - |
TAK-003 | Phase 3 | Dengue Fever | - | - |
TAK-816 | Phase 3 | Healthy Volunteers | - | - |
Brigatinib | Phase 3 | ALK-positive Advanced NSCLC | - | - |
Lapaquistat acetate and atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Cyproterone acetate | Phase 3 | Adenocarcinoma, Prostate | - | - |
Escitalopram | Phase 3 | Treatment Outcome | - | - |
Maribavir | Phase 3 | Cytomegalovirus (CMV) | - | - |
Tetravalent Dengue Vaccine (TDV) | Phase 3 | Dengue Fever | - | - |
TAK-816+ DPT-TAKEDA | Phase 3 | Immunization | - | - |
Lapaquistat acetate and lipid-lowering therapy | Phase 3 | Type 2 Diabetes | - | - |
Glyburide | Phase 3 | Diabetes Mellitus | - | - |
Lapaquistat acetate and additional lipid-lowering therapy | Phase 3 | Hypercholesterolemia | - | - |
Alectinib | Phase 3 | ALK+ Advanced NSCLC | - | - |
HAV Vaccine | Phase 3 | Healthy Volunteers | - | - |
Ramelteon | Phase 3 | Sleep Initiation and Maintenance Disorders | - | - |
TDV | Phase 3 | Dengue Fever | - | - |
Dexlansoprazole MR | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Ixazomib | Phase 3 | Multiple Myeloma | - | - |
SYR-472 | Phase 3 | Diabetes Mellitus | - | - |
TAK-583 | Phase 3 | Neuralgia, Postherpetic | - | - |
Darvadstrocel | Phase 3 | Crohn's Disease | - | - |
Omega-3-acid ethyl esters 90 (TAK-085) | Phase 3 | Hypertriglyceridemia | - | - |
TAK-536CCB | Phase 3 | Grade I or II Essential Hypertension | - | - |
Lansoprazole and naproxen and aspirin | Phase 3 | Osteoarthritis | - | - |
Vedolizumab | Phase 3 | Colitis, Ulcerative | - | - |
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Phase 3 | Colorectal Cancer | - | - |
Rapid-acting insulin secretagogue | Phase 3 | Diabetes Mellitus | - | - |
TAK-861 | Phase 3 | Narcolepsy Type 1 | - | - |
Pioglitazone and Metformin | Phase 3 | Diabetes Mellitus | - | - |
Idursulfase-IT | Phase 3 | Hunter Syndrome | - | - |
Lanadelumab | Phase 3 | Angioedema | - | - |
Candesartan | Phase 3 | Heart Failure | - | - |
Venticute | Phase 3 | Pneumonia | - | - |
Alogliptin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Azilsartan medoxomil - chlorthalidone | Phase 3 | Essential Hypertension | - | - |
Vortioxetine tablets | Phase 3 | Major Depressive Disorder | - | - |
Azilsartan medoxomil | Phase 3 | Essential Hypertension | - | - |
Zasocitinib | Phase 3 | Psoriatic Arthritis | - | - |
Leuprorelin | Phase 3 | Prostatic Neoplasms | - | - |
Resatorvid | Phase 3 | Sepsis | - | - |
Vedolizumab 300 mg IV | Phase 3 | Colitis, Ulcerative | - | - |
Vedolizumab SC 108 mg | Phase 3 | Crohn's Disease | - | - |
TAK-019 | Phase 3 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | - | - |
Alogliptin and glyburide | Phase 3 | Diabetes Mellitus | - | - |
TAK-438 | Phase 3 | Gastric Ulcers | - | - |
SYR-322-MET | Phase 3 | Clinical Pharmacology | - | - |
TAK-438 10 mg | Phase 3 | Non-erosive Gastroesophageal Reflux Disease | - | - |
Vonicog Alfa | Phase 3 | Von Willebrand Disease (VWD) | - | - |
Azilsartan medoxomil and chlorthalidone | Phase 3 | Essential Hypertension | - | - |
Chlorthalidone | Phase 3 | Hypertension | - | - |
Adynovate | Phase 3 | Hemophilia A | - | - |
TAK-411 | Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) | Phase 2 | Dengue Fever | - | - |
Leuprorelin acetate | Phase 2 | Endometriosis | - | - |
Zasocitinib (Dose A) | Phase 2 | Hidradenitis Suppurativa | - | - |
Norwalk VLP vaccine | Phase 2 | Acute Gastroenteritis | - | - |
NoV Vaccine | Phase 2 | Healthy Volunteers | - | - |
TAK-981 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
TAK-954 | Phase 2 | Postoperative Gastrointestinal Dysfunction | - | - |
TAK-079 | Phase 2 | Primary Immune Thrombocytopenia | - | - |
TAK-063 20 mg | Phase 2 | Schizophrenia | - | - |
MCC-135 | Phase 2 | Congestive Heart Failure | - | - |
Brentuximab Vedotin | Phase 2 | Lymphoma | - | - |
Panitumumab + TAS-102 | Phase 2 | Colorectal Cancer | - | - |
Pevonedistat | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
TAK-071 | Phase 2 | Parkinson Disease | - | - |
Leuprorelin (GF) | Phase 2 | Uterine Fibroids | - | - |
Olmesartan | Phase 2 | Hypertension | - | - |
Candesartan cilexetil | Phase 2 | Essential Hypertension | - | - |
Lapaquistat acetate and fenofibrate | Phase 2 | Hyperlipidemias | - | - |
Peginesatide | Phase 2 | Anemia | - | - |
Hepatitis A Vaccine | Phase 2 | Healthy Volunteers | - | - |
NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Norovirus | - | - |
TAK-007 | Phase 2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | - | - |
Ponatinib | Phase 2 | Myeloid Leukemia, Chronic, Chronic Phase | - | - |
TAK-853 | Phase 2 | Ovarian Cancer | - | - |
TAK-850 0.5 mL injection | Phase 2 | Influenza Infection | - | - |
TIMP-GLIA | Phase 2 | Celiac Disease | - | - |
TAK-662 | Phase 2 | Congenital Protein C Deficiency | - | - |
TAK-850 | Phase 2 | Influenza Infection | - | - |
GDX012 | Phase 2 | Leukemia | - | - |
TAK-188 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Levothyroxine sodium new formulation | Phase 2 | Hypothyroidism | - | - |
TD-8954 | Phase 2 | Enteral Feeding Intolerance | - | - |
Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Phase 2 | Dengue Fever | - | - |
TAK-341 | Phase 2 | Multiple System Atrophy | - | - |
Norovirus Bivalent VLP Vaccine | Phase 2 | Norovirus Prevention | - | - |
TAK-442 | Phase 2 | Acute Coronary Syndrome | - | - |
vortioxetine (Lu AA21004) | Phase 2 | Depressive Disorder, Major | - | - |
NDI-034858 | Phase 2 | Psoriatic Arthritis | - | - |
TAK-062 | Phase 2 | Celiac Disease | - | - |
Pioglitazone and insulin | Phase 2 | Diabetes Mellitus | - | - |
Ramelteon and doxepin | Phase 2 | Sleep Initiation and Maintenance Disorders | - | - |
Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Norovirus | - | - |
Subcutaneous injection of TAK-850 | Phase 2 | Influenza Infection | - | - |
TAK-861 2 mg | Phase 2 | Narcolepsy Type 2 | - | - |
TAK-128 | Phase 2 | Diabetic Neuropathies | - | - |
TAK-385 | Phase 2 | Uterine Fibroids | - | - |
TAK-101 | Phase 2 | Celiac Disease | - | - |
Dazostinag | Phase 2 | Solid Neoplasms | - | - |
TAK-919 | Phase 2 | Coronavirus Disease (COVID-19) | - | - |
TAK-783 and methotrexate | Phase 2 | Arthritis, Rheumatoid | - | - |
Norovirus Bivalent Vaccine | Phase 2 | Prevention From Norovirus Infection | - | - |
Ilaprazole | Phase 2 | Esophagitis | - | - |
TDV Liquid Formulation 1 | Phase 2 | Dengue Fever | - | - |
Pioglitazone and atorvastatin | Phase 2 | Cardiovascular Diseases | - | - |
TAK-272 | Phase 2 | Type 2 Diabetes Mellitus and Microalbuminuria | - | - |
GI.1/GII.4 (15/15) | Phase 2 | Norovirus | - | - |
TAK-951 | Phase 2 | Postoperative Nausea and Vomiting (PONV) | - | - |
NDI-034858 study drug | Phase 2 | Moderate to Severe Plaque Psoriasis | - | - |
Namilumab | Phase 2 | Rheumatoid Arthritis | - | - |
TAK-788 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Pioglitazone and ramipril | Phase 2 | Inflammation | - | - |
TAK-935 | Phase 2 | Developmental and/or Epileptic Encephalopathies | - | - |
TAK-715 and methotrexate | Phase 2 | Arthritis, Rheumatoid | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
Pioglitazone and azilsartan | Phase 2 | Diabetes Mellitus | - | - |
psoriasis
2 drugs in this indication
narcolepsy
1 drug in this indication
sleep disorder
1 drug in this indication
Advanced colorectal cancer
1 drug in this indication
Narcolepsy Type 1
1 drug in this indication
Adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and for on-demand treatment and control of bleeding episodes
1 drug in this indication
Fabry Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TAKEDA PHARMACEUTICAL CO LTD's drug pipeline?→
CatalystAlert tracks 200 drug candidates in TAKEDA PHARMACEUTICAL CO LTD's (TAK) pipeline across Phase 3, Phase 2. Its lead program is TAK-559 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TAKEDA PHARMACEUTICAL CO LTD's next FDA catalyst?→
TAKEDA PHARMACEUTICAL CO LTD's (TAK) next tracked catalyst is a Phase 2 expected October 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TAK biotech catalysts?→
Add TAK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TAKEDA PHARMACEUTICAL CO LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.